(Q37964702)

26 August 2017

title

Epigenetic-based therapies in cancer: progress to date (English)

1 reference

26 August 2017

3

Yung-Jue Bang

1 reference

26 August 2017

2

Sae-Won Han

1 reference

26 August 2017

Sang-Hyun Song

1

1 reference

26 August 2017

publication date

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

71

1 reference

26 August 2017

issue

18

1 reference

26 August 2017

page(s)

2391-2403

1 reference

https://scigraph.springernature.com/pub.10.2165/11596690-000000000-00000

26 August 2017

exact match

0 references

cites work

The epigenomics of cancer

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Rethinking how DNA methylation patterns are maintained

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Targeted mutation of the DNA methyltransferase gene results in embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Targeting DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Histone acetylation in chromatin structure and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Histone deacetylase inhibitors: current status and overview of recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Epigenetics and cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Epigenetic regulation in myelodysplastic syndromes: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Targeting DNA methylation for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Discovery of two novel, small-molecule inhibitors of DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

DNA methyltransferase inhibitors-state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Decitabine and its role in the treatment of hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

New nucleoside analogs for patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Zebularine: a new drug for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Preferential response of cancer cells to zebularine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

The crystal structure of Haelll methyltransferase covalently complexed to DNA: An extrahelical cytosine and rearranged base pairing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Demethylating agents in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Decitabine in the treatment of myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Hydralazine target: from blood vessels to the epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Histone deacetylase inhibitors: from target to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Key roles of histone methyltransferase and demethylase in leukemogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596690-000000000-00000

Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A

21 January 2018

1 reference

12 December 2020

Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine

1 reference

12 December 2020

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

1 reference

12 December 2020

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice

1 reference

12 December 2020

Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy

1 reference

12 December 2020

Butyrate and phenylacetate as differentiating agents: practical problems and opportunities.

1 reference

12 December 2020

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

1 reference

12 December 2020

Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma

1 reference

12 December 2020

5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias

1 reference

12 December 2020

10.2165/11596690-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1014837104

0 references

1 reference